Please Wait a Moment
X

CTS History

01Dec

Babesia

SuperUser Account |01 Dec, 2015 | Return|

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

Disaster Reliability via Merged Information Systems

Disaster Reliability via Merged Information Systems

In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...

Read More >
CTS Business Continuity Plan

CTS Business Continuity Plan

As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...

Read More >
Source plasma partners

Source plasma partners

By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...

Read More >
CTS Founded

CTS Founded

In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...

Read More >
Pooled Babesia

Pooled Babesia

Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...

Read More >
Implementation of a COVID-19 Test

Implementation of a COVID-19 Test

CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROSĀ® testing platform to perform COVID-1...

Read More >